Erlotinib in Treating Patients With Locally Advanced or Metastatic Breast Cancer

Completed · Phase 2

Conditions studied: Breast Cancer

In brief

RATIONALE: Biological therapies such as erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor. PURPOSE: Phase II trial to study the effectiveness of erlotinib in treating patients who have locally advanced or metastatic breast cancer.

Key facts

Study ID

NCT00030537

Run by

National Cancer Institute (NCI)

Starts

2001-11-01

Expected to finish

2003-03-01

Last updated by the study team

2013-06-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Center for Cancer Research — Bethesda, Maryland, United States
• Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support — Bethesda, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.